{rfName}
Co

Indexed in

License and use

Citations

65

Altmetrics

Analysis of institutional authors

Pozo Fernández, àngelsAuthorPellise Urquiza, MariaAuthorGrau De Castro, Juan JoseAuthorRodriguez De Miguel, CristinaAuthorHernandez Garcia, CristinaAuthorAlvarez Fernandez, CarmenAuthorMoreira Ruíz, LeticiaAuthorOcaña Bombardo, TeresaAuthorSerradesanferm Fabregas, AnnaAuthorCuatrecasas Freixas, MiriamAuthorReig, AnnaAuthorGarrell Lluís, ImmaAuthorGrau, JAuthorAndreu, MAuthorAuge, JmAuthorCastells, AAuthor
Share
Publications
>
Article

Colorectal Cancer Early Screening Program of Barcelona, Spain: Indicators of the first round of a program with participation of community pharmacies

Publicated to:Medicina Clinica. 145 (4): 141-146 - 2015-08-21 145(4), DOI: 10.1016/j.medcli.2014.05.027

Authors: Buron, Andrea; Grau, Jaume; Andreu, Montserrat; Auge, Josep M; Guayta-Escolies, Rafael; Barau, Merce; Macia, Francesc; Castells, Antoni

Affiliations

Coll Oficial Farmaceut Barcelona, Barcelona, Spain - Author
Consell Coll Farmaceut Catalunya, Direccio Projectes & Recerca, Barcelona, Spain - Author
Hosp Clin Barcelona, CDB, Serv Bioquim & Genet Mol, Barcelona, Spain - Author
Hosp del Mar, Serv Digestol, Barcelona, Spain - Author
Hosp del Mar, Serv Epidemiol & Evaluac, Barcelona, Spain - Author
IMIM Inst Hosp Mar Invest Med, Barcelona, Spain - Author
Red Invest Serv Salud Enfermedades Cron REDISSEC, Barcelona, Spain - Author
Univ Barcelona, Ctr Invest Biomed Red Enfermedades Hepat & Digest, Inst Invest Biomed August Pi & Sunyer IDIBAPS, Serv Gastroenterol,Hosp Clin, Barcelona, Spain - Author
Univ Barcelona, Hosp Clin, Serv Med Prevent & Epidemiol, Barcelona, Spain - Author
See more

Abstract

The Colorectal Cancer Screening Program of Barcelona was implemented in December 2009 and involves pharmacies for the distribution and collection of screening tests. The aim of this article is to describe the main indicators of the first round of the Program (2010-2011), based on the ones suggested by the European Union.The target population of the Colorectal Cancer Screening Program of Barcelona includes men and women aged 50-69 years who live in the catchment areas of Hospital Clínic and Hospital del Mar. Screening consists of biennial immunochemical fecal occult blood testing, with colonoscopy as confirmatory procedure.Target population comprised 197,795 persons. Participation rate was 43.6%, was higher among women and among those aged 60 and older. 2.1% of the eligible population stated to have been already screened for colorectal cancer. Overall positivity rate was 6.2%, higher among men and with a broad variability among health care areas. The detection rates of low- and high-risk adenoma, and of invasive cancer were 9.1 ‰, 21.7 ‰ and 3.1 ‰, respectively. 48.2% of tumors were stage i.These results are considered satisfactory and consistent with those obtained in other programs and with European standards. Nevertheless, some areas for improvement have been identified. The high participation rate can be attributed, at least in part, to the type of test and to the involvement of community pharmacies.Copyright © 2014 Elsevier España, S.L.U. All rights reserved.

Keywords
average-risk populationcáncer colorrectalcancer early detectioncancer screeningcolorectal cancercommunity pharmacy servicescribadodiagnóstico precozfarmacia comunitariagendermortalityAverage-risk populationCancer colorrectalCancer early detectionCancer screeningCataloniaColorectal cancerCommunity pharmacy servicesDiagnóstico precozFarmacia comunitariaGenderMortalityOccult blood-testPalabras clave cribadoPoblación de riesgo intermedioPopulation

Quality index

Bibliometric impact. Analysis of the contribution and dissemination channel

The work has been published in the journal Medicina Clinica due to its progression and the good impact it has achieved in recent years, according to the agency WoS (JCR), it has become a reference in its field. In the year of publication of the work, 2015, it was in position 76/155, thus managing to position itself as a Q2 (Segundo Cuartil), in the category Medicine, General & Internal. Notably, the journal is positioned en el Cuartil Q3 para la agencia Scopus (SJR) en la categoría Medicine (Miscellaneous).

From a relative perspective, and based on the normalized impact indicator calculated from World Citations from Scopus Elsevier, it yields a value for the Field-Weighted Citation Impact from the Scopus agency: 2.03, which indicates that, compared to works in the same discipline and in the same year of publication, it ranks as a work cited above average. (source consulted: ESI Nov 14, 2024)

This information is reinforced by other indicators of the same type, which, although dynamic over time and dependent on the set of average global citations at the time of their calculation, consistently position the work at some point among the top 50% most cited in its field:

  • Field Citation Ratio (FCR) from Dimensions: 5.83 (source consulted: Dimensions Apr 2025)

Specifically, and according to different indexing agencies, this work has accumulated citations as of 2025-04-30, the following number of citations:

  • WoS: 25
  • Scopus: 28
  • Europe PMC: 12
  • OpenCitations: 25
Impact and social visibility

From the perspective of influence or social adoption, and based on metrics associated with mentions and interactions provided by agencies specializing in calculating the so-called "Alternative or Social Metrics," we can highlight as of 2025-04-30:

  • The use of this contribution in bookmarks, code forks, additions to favorite lists for recurrent reading, as well as general views, indicates that someone is using the publication as a basis for their current work. This may be a notable indicator of future more formal and academic citations. This claim is supported by the result of the "Capture" indicator, which yields a total of: 46 (PlumX).
Leadership analysis of institutional authors

There is a significant leadership presence as some of the institution’s authors appear as the first or last signer, detailed as follows: Last Author (Castells Garangou, Antoni).